KR102259085B1 - Edb 표적화 il-12 조성물 - Google Patents

Edb 표적화 il-12 조성물 Download PDF

Info

Publication number
KR102259085B1
KR102259085B1 KR1020207025138A KR20207025138A KR102259085B1 KR 102259085 B1 KR102259085 B1 KR 102259085B1 KR 1020207025138 A KR1020207025138 A KR 1020207025138A KR 20207025138 A KR20207025138 A KR 20207025138A KR 102259085 B1 KR102259085 B1 KR 102259085B1
Authority
KR
South Korea
Prior art keywords
ser
delete delete
gly
leu
thr
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Active
Application number
KR1020207025138A
Other languages
English (en)
Korean (ko)
Other versions
KR20200109380A (ko
Inventor
알레산드라 빌라
마띠아 마타씨
티치아노 온가로
Original Assignee
필로겐 에스.피.에이.
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by 필로겐 에스.피.에이. filed Critical 필로겐 에스.피.에이.
Priority to KR1020217015607A priority Critical patent/KR102488801B1/ko
Publication of KR20200109380A publication Critical patent/KR20200109380A/ko
Application granted granted Critical
Publication of KR102259085B1 publication Critical patent/KR102259085B1/ko
Active legal-status Critical Current
Anticipated expiration legal-status Critical

Links

Images

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides
    • A61K38/16—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • A61K38/17—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • A61K38/19—Cytokines; Lymphokines; Interferons
    • A61K38/20—Interleukins [IL]
    • A61K38/208—IL-12
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • C07K14/435—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • C07K14/52—Cytokines; Lymphokines; Interferons
    • C07K14/54—Interleukins [IL]
    • C07K14/5434—IL-12
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/50—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates
    • A61K47/51—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent
    • A61K47/62—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent the modifying agent being a protein, peptide or polyamino acid
    • A61K47/65—Peptidic linkers, binders or spacers, e.g. peptidic enzyme-labile linkers
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/50—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates
    • A61K47/51—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent
    • A61K47/68—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent the modifying agent being an antibody, an immunoglobulin or a fragment thereof, e.g. an Fc-fragment
    • A61K47/6801—Drug-antibody or immunoglobulin conjugates defined by the pharmacologically or therapeutically active agent
    • A61K47/6803—Drugs conjugated to an antibody or immunoglobulin, e.g. cisplatin-antibody conjugates
    • A61K47/6811—Drugs conjugated to an antibody or immunoglobulin, e.g. cisplatin-antibody conjugates the drug being a protein or peptide, e.g. transferrin or bleomycin
    • A61K47/6813—Drugs conjugated to an antibody or immunoglobulin, e.g. cisplatin-antibody conjugates the drug being a protein or peptide, e.g. transferrin or bleomycin the drug being a peptidic cytokine, e.g. an interleukin or interferon
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/50—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates
    • A61K47/51—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent
    • A61K47/68—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent the modifying agent being an antibody, an immunoglobulin or a fragment thereof, e.g. an Fc-fragment
    • A61K47/6835—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent the modifying agent being an antibody, an immunoglobulin or a fragment thereof, e.g. an Fc-fragment the modifying agent being an antibody or an immunoglobulin bearing at least one antigen-binding site
    • A61K47/6843—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent the modifying agent being an antibody, an immunoglobulin or a fragment thereof, e.g. an Fc-fragment the modifying agent being an antibody or an immunoglobulin bearing at least one antigen-binding site the antibody targeting a material from animals or humans
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/50—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates
    • A61K47/51—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent
    • A61K47/68—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent the modifying agent being an antibody, an immunoglobulin or a fragment thereof, e.g. an Fc-fragment
    • A61K47/6835—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent the modifying agent being an antibody, an immunoglobulin or a fragment thereof, e.g. an Fc-fragment the modifying agent being an antibody or an immunoglobulin bearing at least one antigen-binding site
    • A61K47/6851—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent the modifying agent being an antibody, an immunoglobulin or a fragment thereof, e.g. an Fc-fragment the modifying agent being an antibody or an immunoglobulin bearing at least one antigen-binding site the antibody targeting a determinant of a tumour cell
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/50—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates
    • A61K47/51—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent
    • A61K47/68—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent the modifying agent being an antibody, an immunoglobulin or a fragment thereof, e.g. an Fc-fragment
    • A61K47/6889—Conjugates wherein the antibody being the modifying agent and wherein the linker, binder or spacer confers particular properties to the conjugates, e.g. peptidic enzyme-labile linkers or acid-labile linkers, providing for an acid-labile immuno conjugate wherein the drug may be released from its antibody conjugated part in an acidic, e.g. tumoural or environment
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • C07K14/435—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • C07K14/78—Connective tissue peptides, e.g. collagen, elastin, laminin, fibronectin, vitronectin or cold insoluble globulin [CIG]
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K16/00—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies
    • C07K16/18—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from animals or humans
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/60—Immunoglobulins specific features characterized by non-natural combinations of immunoglobulin fragments
    • C07K2317/62—Immunoglobulins specific features characterized by non-natural combinations of immunoglobulin fragments comprising only variable region components
    • C07K2317/622—Single chain antibody (scFv)
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/60—Immunoglobulins specific features characterized by non-natural combinations of immunoglobulin fragments
    • C07K2317/62—Immunoglobulins specific features characterized by non-natural combinations of immunoglobulin fragments comprising only variable region components
    • C07K2317/626—Diabody or triabody
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2319/00—Fusion polypeptide
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2319/00—Fusion polypeptide
    • C07K2319/33—Fusion polypeptide fusions for targeting to specific cell types, e.g. tissue specific targeting, targeting of a bacterial subspecies
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2319/00—Fusion polypeptide
    • C07K2319/70—Fusion polypeptide containing domain for protein-protein interaction
    • C07K2319/74—Fusion polypeptide containing domain for protein-protein interaction containing a fusion for binding to a cell surface receptor
    • C07K2319/75—Fusion polypeptide containing domain for protein-protein interaction containing a fusion for binding to a cell surface receptor containing a fusion for activation of a cell surface receptor, e.g. thrombopoeitin, NPY and other peptide hormones

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Engineering & Computer Science (AREA)
  • Medicinal Chemistry (AREA)
  • General Health & Medical Sciences (AREA)
  • Organic Chemistry (AREA)
  • Public Health (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Veterinary Medicine (AREA)
  • Animal Behavior & Ethology (AREA)
  • Immunology (AREA)
  • Epidemiology (AREA)
  • Molecular Biology (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Zoology (AREA)
  • Biochemistry (AREA)
  • Biophysics (AREA)
  • Genetics & Genomics (AREA)
  • Gastroenterology & Hepatology (AREA)
  • Toxicology (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • General Chemical & Material Sciences (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Cell Biology (AREA)
  • Peptides Or Proteins (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Preparation Of Compounds By Using Micro-Organisms (AREA)
  • Medicinal Preparation (AREA)
  • Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)
  • Micro-Organisms Or Cultivation Processes Thereof (AREA)
KR1020207025138A 2018-02-09 2019-02-08 Edb 표적화 il-12 조성물 Active KR102259085B1 (ko)

Priority Applications (1)

Application Number Priority Date Filing Date Title
KR1020217015607A KR102488801B1 (ko) 2018-02-09 2019-02-08 Edb 표적화 il-12 조성물

Applications Claiming Priority (5)

Application Number Priority Date Filing Date Title
EP18156141 2018-02-09
EP18156141.6 2018-02-09
EP18179313 2018-06-22
EP18179313.4 2018-06-22
PCT/EP2019/053136 WO2019154986A1 (en) 2018-02-09 2019-02-08 Edb targeting il-12 compositions

Related Child Applications (1)

Application Number Title Priority Date Filing Date
KR1020217015607A Division KR102488801B1 (ko) 2018-02-09 2019-02-08 Edb 표적화 il-12 조성물

Publications (2)

Publication Number Publication Date
KR20200109380A KR20200109380A (ko) 2020-09-22
KR102259085B1 true KR102259085B1 (ko) 2021-06-03

Family

ID=65268973

Family Applications (2)

Application Number Title Priority Date Filing Date
KR1020207025138A Active KR102259085B1 (ko) 2018-02-09 2019-02-08 Edb 표적화 il-12 조성물
KR1020217015607A Active KR102488801B1 (ko) 2018-02-09 2019-02-08 Edb 표적화 il-12 조성물

Family Applications After (1)

Application Number Title Priority Date Filing Date
KR1020217015607A Active KR102488801B1 (ko) 2018-02-09 2019-02-08 Edb 표적화 il-12 조성물

Country Status (25)

Country Link
US (1) US12173044B2 (https=)
EP (1) EP3749372B1 (https=)
JP (2) JP7279054B2 (https=)
KR (2) KR102259085B1 (https=)
CN (1) CN111683687B (https=)
AU (2) AU2019219201B2 (https=)
BR (1) BR112020012888A2 (https=)
CA (1) CA3087488C (https=)
CL (1) CL2020002052A1 (https=)
CO (1) CO2020009737A2 (https=)
CR (1) CR20200342A (https=)
CU (1) CU20200054A7 (https=)
EC (1) ECSP20047171A (https=)
ES (1) ES3035714T3 (https=)
IL (1) IL275713A (https=)
JO (1) JOP20200193A1 (https=)
MX (1) MX2020008231A (https=)
MY (1) MY200700A (https=)
PE (1) PE20210122A1 (https=)
PH (1) PH12020551230A1 (https=)
RU (2) RU2758143C1 (https=)
SG (1) SG11202006334XA (https=)
TW (1) TWI844524B (https=)
UY (1) UY38074A (https=)
WO (1) WO2019154986A1 (https=)

Cited By (1)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
KR20200078193A (ko) * 2018-12-21 2020-07-01 가톨릭대학교 산학협력단 p40-EBI3의 복합체 및 이의 용도

Families Citing this family (11)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
TWI844524B (zh) * 2018-02-09 2024-06-11 義大利商費洛根公司 靶向edb之il-12組合物
EP3856763A1 (en) 2018-09-28 2021-08-04 Massachusetts Institute of Technology Collagen-localized immunomodulatory molecules and methods thereof
CA3150224A1 (en) 2019-09-10 2021-03-18 Obsidian Therapeutics, Inc. Ca2 compositions and methods for tunable regulation
US20230312726A1 (en) * 2020-04-14 2023-10-05 Philogen S.P.A. Dosage units and regimen, uses, methods or formulations of compositions comprising a recombinant protein comprising interleukin-12 and an antibody binding the extra-domain b of fibronectin
KR102649794B1 (ko) * 2020-10-19 2024-03-22 고려대학교 산학협력단 암 및/또는 뇌질환 바이오마커인 엑스트라-도메인 b 파이브로넥틴 및 이를 이용한 진단 방법
AU2023206004B2 (en) * 2022-01-04 2025-04-17 Philogen S.P.A. Combination of an immunocytokine comprising il-12 and a kinase inhibitor
CN118359730A (zh) * 2023-01-17 2024-07-19 上海君赛生物科技有限公司 包含细胞因子的靶向型融合蛋白
WO2025061801A1 (en) 2023-09-19 2025-03-27 Philochem Ag Therapeutic combination of an anti-edb fibronectin domain antibody il2 or il12 fusion protein and a lutetium-177 radioconjugate
WO2025251110A1 (en) * 2024-06-03 2025-12-11 Selvax Pty Ltd Anti-cd40 antibody il-2 fusion proteins
WO2026003203A1 (en) 2024-06-27 2026-01-02 Philogen S.P.A. Combination of an immunocytokine comprising targeted il2 and a jak inhibitor
WO2026013184A1 (en) 2024-07-10 2026-01-15 Ac Immune Sa Fusion protein peptide linkers and uses thereof

Citations (3)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO2006119897A2 (en) 2005-05-11 2006-11-16 Philogen S.P.A Fusion protein of antibody l19 against fibronectin ed-b and interleukin 12
WO2011020783A2 (en) 2009-08-17 2011-02-24 Roche Glycart Ag Targeted immunoconjugates
WO2013014149A1 (en) 2011-07-27 2013-01-31 Philogen S.P.A. Il-12 immunoconjugate

Family Cites Families (12)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US5595756A (en) * 1993-12-22 1997-01-21 Inex Pharmaceuticals Corporation Liposomal compositions for enhanced retention of bioactive agents
US5994104A (en) * 1996-11-08 1999-11-30 Royal Free Hospital School Of Medicine Interleukin-12 fusion protein
JP2003524018A (ja) 2000-02-24 2003-08-12 アイトゲネーシシェ テクニシェ ホッホシューレ チューリッヒ フィブロネクチンのｅｄ‐ｂドメインに特異的な抗体、前記抗体を含む複合体、および血管形成を検出および治療するためのその使用
ATE333900T1 (de) * 2000-02-24 2006-08-15 Philogen Spa Zusamensetzungen und verfahren zur behandlung von angiogenese in pathologischen schädigungen
CN100535013C (zh) 2002-03-11 2009-09-02 菲洛根股份公司 应用抗体分子对肿瘤血管进行选择性定向
AU2005203962C1 (en) * 2004-01-05 2012-11-08 Antisoma Research Limited Interleukin-12 targeted to oncofoetal fibronectin
US8580267B2 (en) * 2008-12-19 2013-11-12 Philogen S.P.A. Immunocytokines for tumour therapy with chemotherapeutic agents
AU2014257906A1 (en) * 2013-04-26 2015-12-10 Philogen S.P.A. IL4 conjugated to antibodies against extracellular matrix components
SG11201802912PA (en) * 2015-10-10 2018-05-30 Intrexon Corp Improved therapeutic control of proteolytically sensitive, destabilized forms of interleukin-12
WO2018153865A1 (en) 2017-02-24 2018-08-30 Philogen S.P.A. Immunoconjugates with optimized linkers and orientation
WO2018224550A1 (en) * 2017-06-07 2018-12-13 Philogen S.P.A Vascular endothelial growth factor/anti-fibronectin antibody fusion proteins
TWI844524B (zh) * 2018-02-09 2024-06-11 義大利商費洛根公司 靶向edb之il-12組合物

Patent Citations (3)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO2006119897A2 (en) 2005-05-11 2006-11-16 Philogen S.P.A Fusion protein of antibody l19 against fibronectin ed-b and interleukin 12
WO2011020783A2 (en) 2009-08-17 2011-02-24 Roche Glycart Ag Targeted immunoconjugates
WO2013014149A1 (en) 2011-07-27 2013-01-31 Philogen S.P.A. Il-12 immunoconjugate

Cited By (3)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
KR20200078193A (ko) * 2018-12-21 2020-07-01 가톨릭대학교 산학협력단 p40-EBI3의 복합체 및 이의 용도
KR102524247B1 (ko) 2018-12-21 2023-04-21 가톨릭대학교 산학협력단 p40-EBI3의 복합체 및 이의 용도
US12492235B2 (en) 2018-12-21 2025-12-09 The Catholic University Of Korea Foundation Industry-Academic Cooperation Cytokines and use thereof

Also Published As

Publication number Publication date
TW201934136A (zh) 2019-09-01
ES3035714T3 (en) 2025-09-08
JP2023113648A (ja) 2023-08-16
EP3749372C0 (en) 2025-04-16
EP3749372B1 (en) 2025-04-16
KR20200109380A (ko) 2020-09-22
CL2020002052A1 (es) 2021-01-04
PE20210122A1 (es) 2021-01-19
IL275713A (en) 2020-08-31
CO2020009737A2 (es) 2020-08-21
AU2019219201A1 (en) 2020-07-23
RU2021130306A (ru) 2021-11-10
MY200700A (en) 2024-01-11
AU2021203986A1 (en) 2021-07-08
CA3087488C (en) 2021-11-02
CR20200342A (es) 2020-10-19
US20200397915A1 (en) 2020-12-24
JOP20200193A1 (ar) 2020-08-06
CN111683687B (zh) 2024-08-02
AU2019219201B2 (en) 2021-07-08
MX2020008231A (es) 2020-09-25
RU2758143C1 (ru) 2021-10-26
CU20200054A7 (es) 2021-05-12
NZ766787A (en) 2024-05-31
UY38074A (es) 2019-10-01
US12173044B2 (en) 2024-12-24
TWI844524B (zh) 2024-06-11
CA3087488A1 (en) 2019-08-15
ECSP20047171A (es) 2020-09-30
PH12020551230A1 (en) 2021-05-17
KR20210063467A (ko) 2021-06-01
JP7279054B2 (ja) 2023-05-22
CN111683687A (zh) 2020-09-18
WO2019154986A1 (en) 2019-08-15
JP2021513536A (ja) 2021-05-27
BR112020012888A2 (pt) 2020-12-08
KR102488801B1 (ko) 2023-01-13
SG11202006334XA (en) 2020-08-28
EP3749372A1 (en) 2020-12-16

Similar Documents

Publication Publication Date Title
KR102259085B1 (ko) Edb 표적화 il-12 조성물
JP7701197B2 (ja) 抗薬物抗体の形成を減少させるためのｉｉ型抗ｃｄ２０抗体
JP7273101B2 (ja) Ｃｄ３８に結合する抗体治療剤
CN116261595A (zh) 抗vegf-抗pd-l1双特异性抗体、其药物组合物及用途
MX2014013866A (es) Anticuerpos cd33 y su uso para tratar cancer.
TW202221021A (zh) 改良之抗原結合受體
JP7689116B2 (ja) Ｐｄ１およびｖｅｇｆｒ２二重結合剤
CA3117371A1 (en) Methods of administering anti-tim-3 antibodies
CN115192718A (zh) 抗cd47的单克隆抗体及其用途
WO2021214329A1 (en) Composition comprising an ige antibody
KR20220047982A (ko) 암의 치료를 위한 인테그린-표적화 노틴-fc 융합 및 항-cd47 항체의 조합물
CA3208339A1 (en) Compositions comprising 4-1bb and ox40 binding proteins and methods of use
EA043910B1 (ru) Иммуноцитокин для нацеленной на злокачественную опухоль доставки il-12 и его применение
WO2025131063A1 (en) Antibody drug conjugates targeting b7-h3 and trop2 and the use thereof
WO2024165403A1 (en) Anti-cea antibodies
JP2025541150A (ja) Ｃｄ４７遮断薬と抗ｃｄ２０／抗ｃｄ３二重特異性抗体との併用療法
WO2025106598A1 (en) Modified mana-tces targeting tumor antigens and engaging t cell receptors, and methods of using thereof
CN120530135A (zh) 抗b7h3抗体和使用方法
HK40081642A (en) Anti-cd47 monoclonal antibody and use thereof
EP4139356A1 (en) Composition comprising an ige antibody
HK1258057B (en) Type ii anti-cd20 antibody for reducing formation of anti-drug antibodies
BR112014028507B1 (pt) Anticorpos cd33 e uso dos mesmos para tratar câncer

Legal Events

Date Code Title Description
PA0105 International application

St.27 status event code: A-0-1-A10-A15-nap-PA0105

A201 Request for examination
A302 Request for accelerated examination
E13-X000 Pre-grant limitation requested

St.27 status event code: A-2-3-E10-E13-lim-X000

P11-X000 Amendment of application requested

St.27 status event code: A-2-2-P10-P11-nap-X000

P13-X000 Application amended

St.27 status event code: A-2-2-P10-P13-nap-X000

PA0201 Request for examination

St.27 status event code: A-1-2-D10-D11-exm-PA0201

PA0302 Request for accelerated examination

St.27 status event code: A-1-2-D10-D17-exm-PA0302

St.27 status event code: A-1-2-D10-D16-exm-PA0302

PG1501 Laying open of application

St.27 status event code: A-1-1-Q10-Q12-nap-PG1501

E902 Notification of reason for refusal
PE0902 Notice of grounds for rejection

St.27 status event code: A-1-2-D10-D21-exm-PE0902

E13-X000 Pre-grant limitation requested

St.27 status event code: A-2-3-E10-E13-lim-X000

P11-X000 Amendment of application requested

St.27 status event code: A-2-2-P10-P11-nap-X000

P13-X000 Application amended

St.27 status event code: A-2-2-P10-P13-nap-X000

E701 Decision to grant or registration of patent right
PE0701 Decision of registration

St.27 status event code: A-1-2-D10-D22-exm-PE0701

A107 Divisional application of patent
PA0104 Divisional application for international application

St.27 status event code: A-0-1-A10-A18-div-PA0104

St.27 status event code: A-0-1-A10-A16-div-PA0104

GRNT Written decision to grant
PR0701 Registration of establishment

St.27 status event code: A-2-4-F10-F11-exm-PR0701

PR1002 Payment of registration fee

St.27 status event code: A-2-2-U10-U12-oth-PR1002

Fee payment year number: 1

PG1601 Publication of registration

St.27 status event code: A-4-4-Q10-Q13-nap-PG1601

PR1001 Payment of annual fee

St.27 status event code: A-4-4-U10-U11-oth-PR1001

Fee payment year number: 4

PR1001 Payment of annual fee

St.27 status event code: A-4-4-U10-U11-oth-PR1001

Fee payment year number: 5

U11 Full renewal or maintenance fee paid

Free format text: ST27 STATUS EVENT CODE: A-4-4-U10-U11-OTH-PR1001 (AS PROVIDED BY THE NATIONAL OFFICE)

Year of fee payment: 5